Health Care & Life Sciences » Pharmaceuticals | Summit Therapeutics PLC

Summit Therapeutics PLC

Summit Therapeutics PLC
Stock Exchange London Stock Exchange
EPS
 GBP0.15
Market Cap
 GBP38.12 M
Shares Outstanding
 82.13 M
Public Float
 76.37 M
Summit Therapeutics PLC ADR
Stock Exchange NASDAQ Stock Market
EPS
 $1
Market Cap
 $41.41 M
Shares Outstanding
 32.1 M
Public Float
 -

Profile

Address
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
Employees -
Website http://summitplc.com
Updated 07/08/2019
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom.

Financials

View All
Created with Highcharts 5.0.14Summit Therapeutics PLCNet Income. Fiscal year is February-January. All values GBP Thousands.6 0936 09311 36311 36320 13720 13721 37121 3717 1317 1317 5277 52720142015201620172018201905k10k15k20k25k
Created with Highcharts 5.0.14Summit Therapeutics PLCSales/Revenue. Fiscal year is February-January. All values GBP Thousands.1 3751 3751 1691 1695925922 3172 31725 41925 41943 01243 012201420152016201720182019010k20k30k40k50k

Glyn O. Edwards
Chief Executive Officer & Executive Director
Frank Murdoch Armstrong
Non-Executive Chairman
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.